What Is Foundayo? Uses, Dosage, and What You Need to Know in 2026

Foundayo is a prescription weight loss medication that was FDA-approved on April 1, 2026. Made by Eli Lilly, it's the first small-molecule oral GLP-1 receptor agonist approved for chronic weight management — and the only GLP-1 pill that can be taken at any time of day without food or water restrictions. If you've heard about Foundayo and want to understand what it is and whether it might be right for you, this guide has everything you need.

What Is Foundayo?

Foundayo is the brand name for orforglipron (pronounced or-FOR-glip-ron), a glucagon-like peptide-1 (GLP-1) receptor agonist in tablet form. It belongs to the same class of medications as Wegovy (semaglutide) and Zepbound (tirzepatide) — the widely discussed weight loss injections — but it comes as a daily pill rather than a weekly injection.

What makes Foundayo structurally different is that it's a small molecule, not a peptide. Most other GLP-1 drugs are peptide-based, which means they're made of chains of amino acids (like a protein) and must be injected because digestive enzymes would break them down if swallowed. Orforglipron's small-molecule structure survives digestion, making reliable oral absorption possible.

Foundayo was originally discovered by Chugai Pharmaceutical and licensed by Eli Lilly in 2018. Lilly developed it through Phase 3 clinical trials and received FDA approval in a historic 50-day review under the Commissioner's National Priority Voucher program — the fastest new molecular entity approval since 2002.

What Is Foundayo Approved For?

Foundayo is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in:

• Adults with obesity (BMI of 30 kg/m² or higher)
• Adults who are overweight (BMI of 27–29.9 kg/m²) with at least one weight-related medical condition, such as: high blood pressure, type 2 diabetes, high cholesterol, obstructive sleep apnea, or PCOS

It is NOT currently FDA-approved for type 2 diabetes on its own (though a diabetes application is expected to be submitted by Lilly), and it has not been approved for use in children.

How Well Does Foundayo Work? Clinical Trial Results

Foundayo's effectiveness was established in the Phase 3 ATTAIN clinical trial program — two large, global, 72-week trials involving more than 4,500 people:

• ATTAIN-1 (adults with obesity/overweight, no diabetes): Patients on the highest dose (17.2 mg) who completed treatment lost an average of 27.3 pounds (12.4% of body weight) at 72 weeks, vs. 2.2 pounds (0.9%) with placebo. All participants regardless of completion averaged 25 lbs (11.1%) vs. 5.3 lbs (2.1%) with placebo.
• ATTAIN-2 (adults with obesity/overweight and type 2 diabetes): Highest dose produced 10.5% weight reduction and A1C reduction of 1.3–1.8% from a baseline of 8.1% at 72 weeks. 75% of patients on the highest dose achieved A1C ≤6.5%.

The drug also reduced cardiovascular risk markers across all doses, including waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure.

Foundayo Dosage: How to Take It

Foundayo comes in six tablet strengths: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg. You start at the lowest dose and work up gradually:

1. Start: 0.8 mg once daily
2. After ≥30 days: Increase to 2.5 mg once daily
3. After ≥30 more days: Increase to 5.5 mg once daily
4. Can continue increasing (≥30 days at each level) to 9 mg, 14.5 mg, and 17.2 mg based on tolerability and treatment response

How to take it: Once daily orally — at any time of day, with or without food, with no water quantity restrictions. This is a significant advantage over the oral Wegovy pill, which requires fasting and limited water intake.

If you miss 7 or more consecutive doses, restart at a lower dose to reduce GI side effect risk when resuming.

Who Should NOT Take Foundayo?

Foundayo is contraindicated in people with:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Severe hepatic impairment (Child-Pugh Class C)

Is Foundayo a Controlled Substance?

No. Foundayo is not a controlled substance under the DEA Controlled Substances Act. It has no scheduled status and no addiction or dependence potential. Any licensed prescriber — including your primary care doctor, NP, or PA — can write a prescription without special DEA authorization.

How to Get Foundayo

You need a prescription from a licensed healthcare provider. Once you have one, ask your doctor to route it to LillyDirect for the most reliable current access. For help finding a pharmacy near you, medfinder calls pharmacies on your behalf. For information on costs and savings programs, see our guide on how to save money on Foundayo in 2026.